Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Cardiovascular >> Blood >> Serum Proteins
Anti-Von Willebrand Factor antibody (FITC)
See all Von Willebrand Factor products (23) ...
Sheep polyclonal to Von Willebrand Factor (FITC)
FITC
Fluorescein Isothiocyante (FITC)
The unconjugated immunoglobulin gives no arcs when tested by immunoelectrophoresis against human serum. Identity has been confirmed by double diffusion (Ouchterlony) against von Willebrand Factor and an anti-von Willebrand Factor of known specificity.
IHC-Fr, ICC/IF, Flow Cytmore details
Reacts with
Rat, Human
Human Von Willebrand Factor Antigen prepared from citrated human plasma. Greater than 95% purity by SDS-PAGE.
Direct on frozen sections of human tonsil.
Liquid
Store at +4°C.
PBS, pH 7.2, sodium azide, 0.1%
Concentration information loading...
Immunogen affinity purified
Polyclonal
unknown
IgG
unknown
Stem Cells >> Endothelial Progenitors >> Endothelial Markers
Cancer >> Invasion/microenvironment >> Angiogenesis >> Angiogenic growth factors
Cardiovascular >> Blood >> Coagulation >> Regulatory
Cardiovascular >> Blood >> Coagulation >> Extrinsic
Cardiovascular >> Blood >> Platelets
Cardiovascular >> Blood >> Serum Proteins
Our Abpromise guarantee covers the use of ab8822 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-Fr: 1/50 - 1/100.
ICC/IF: Use at an assay dependent dilution. (PubMed: 20448112)
Flow Cyt: Use at an assay dependent concentration. (PubMed: 21050042)
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Plasma.
Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Contains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
All cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
Target information above from: UniProt accessionP04275
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
This product has been referenced in:
See all 3 publications for this product
Publishing research using ab8822? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
